美国心脏病学院和美国心脏协会在冠状动脉心肌血运重建指南2021年版中，将冠状动脉旁路移植术（CABG）治疗冠心病三支病变从原先的Ⅰ类推荐降为Ⅱb类推荐，并将桡动脉作为旁路材料从原先的Ⅱa类推荐提升为Ⅰ类推荐，上述变化受到各国心脏外科医师和多个心脏外科协会及学会的关注和质疑，集中在作为证据的ISCHEMIA研究存在明显的选择偏倚，未考虑CABG在合并高危因素的患者中的长期通畅率优势，以及未明确桡动脉旁路有明确的适用人群。广泛收集、谨慎遴选证据，与多学科团队中的心脏外科医师紧密合作，才能形成更合理更全面的指南建议。“,”The 2021 ACC/AHA/SCAI Guideline For Coronary Artery Revascularization has been brought into focus and widely questioned by multiple associations for cardiac surgery around the world, in which the class of recommendation (COR) for coronary artery bypass grafting (CABG) was downgraded from Ⅰ to Ⅱb in the treatment of 3 vessel coronary artery disease, and the use of radial artery as CABG conduit was elevated to COR Ⅰ. The ISCHEMIA trial, which was cited by the guidelines as evidence, had obvious selection bias when it was included in patients with CABG. It did not consider the advantages of long-term patency rate of CABG in patients with high risk factors, and did not define that radial artery bypass has a certain applicable population. Only by widely collecting and carefully selecting evidence and working closely with cardiac surgeons in the multidisciplinary team of coronary heart disease, the more reasonable and comprehensive guidelines and suggestions could be formed.